Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis

This study has been terminated.
Sponsor:
Information provided by:
Helix Medical Systems
ClinicalTrials.gov Identifier:
NCT00355745
First received: July 22, 2006
Last updated: June 8, 2011
Last verified: May 2008

July 22, 2006
June 8, 2011
July 2006
December 2008   (final data collection date for primary outcome measure)
Occurrences of adverse events [ Time Frame: immediately ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00355745 on ClinicalTrials.gov Archive Site
Quality of ultrasound imaging [ Time Frame: within 1 day ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis
Not Provided

In the United States, breast cancer is the most common cancer occurring in women (excluding cancers of the skin) and the second most common cause of death from cancer in women (after lung cancer). Approximately 182,800 new cases per year occur in the United States, causing 40,800 death cases per year. Breast cancer is the leading cause of death in women aged 44-50 years. The 5-year survival rate is 60% overall but is greater than 80% for early disease.

If diagnosed at an early stage, breast cancer has an encouraging cure rate: up to 97% of women diagnosed with localized breast cancer will survive five years after their diagnosis. Even if the cancer is found at a more advanced stage, new therapies have enabled many people with breast cancer to experience the same quality of life as before their diagnosis.

Breast ultrasound (US) is an extremely useful modality in the diagnosis of breast disease in the symptomatic clinic. It is routinely used as an adjunct to x-ray mammography and clinical examination and, with younger patients it may be the sole imaging modality. It has well-established value in differentiating between malignant and benign solid lesions in some cases, however, it cannot replace fine needle aspiration and core biopsy.

Conventional breast US scanning is highly operator- dependent, requiring skillful probe manipulation and the mental ability to envisage 3-D tissue structure. Acquiring 3-D US data sets may be advantageous, making it easier to see and interpret 3-D structures, boundaries and interactions.

CBUS™, Circular Breast Ultrasound Scanner is indicated to improve significantly breast images obtained by ultrasound systems. The CBUS™ system automatically acquires a complete breast image and constructs a high quality 3D image of the scanned breast. These images provide diagnostic information of the complete volume of breast tissue including blood flow in a single ultrasonic 3D image.

In this clinical study, the CBUS™ Circular Breast Ultrasound Scanner will be used to automatically image the complete breast and provides a high quality 3D image of the scanned breast.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Breast Cancer
Device: Ultrasound breast scanning
breast scanning
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
50
July 2009
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female age between 21-70 years.
  • Subject has mammography or ultrasound findings
  • Subject is scheduled for biopsy.
  • Subject is scheduled for ultrasound breast scan.
  • Subject understands the study procedure.
  • Subject is willing to sign the inform consent and comply with the study requirements.

Exclusion Criteria:

  • Age < 21 years or > 70 years.
  • Subject undergo previous breast surgery
  • Known blood coagulation disorders.
  • Known cardiac disorders.
  • Breast infection / breast abscess / breast pains.
  • Ipsilateral breast scar in same quadrant as current lesion
  • Recent breast trauma.
  • Pregnant or lactating woman
  • Subject has bleeding disorder.
  • Subject is suffering extreme general weakness.
  • Subject objects to the study protocol.
  • Physician objection.
  • Known cognitive or psychiatric disorder
  • Participation in any other clinical trial
Female
21 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00355745
CBUS -RA-001
Not Provided
Dr. Hanna Levy, Clinical Study Consultant, Helix Medical Ltd
Helix Medical Systems
Not Provided
Study Director: Hanna Levy, PhD Rambam Health Care Campus
Helix Medical Systems
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP